IOncology

On November 15, 2024, the 4th Asian Oncology Society opened grandly in Xi'an, China. Held alongside the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), this event, co-hosted by the Chinese Anti-Cancer Association and the Asian Oncology Society (AOS), was themed "Integration and Modernity." It brought together oncology experts from across Asia to explore new cancer control strategies and clinical practice advancements. During the conference, Oncology Frontier had the privilege of interviewing Prof. Han Kwang Yang, Secretary-General of AOS and a renowned expert from Seoul National University Hospital, to discuss AOS’s mission and vision for the future.

From November 14–17, the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Society (AOS 2024) convened in Xi'an. Jointly organized by the Chinese Anti-Cancer Association (CACA), the Union for International Cancer Control (UICC), and the National Comprehensive Cancer Network (NCCN®), the event featured a specialized session on "International Collaboration: CACA-UICC & CACA-NCCN."

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) recently convened in Xi'an, bringing together global experts and scholars to discuss the latest advancements in cancer treatment and foster international cooperation. Among the distinguished participants was Prof. Naoufal Louati, President of the Moroccan Institute of Traditional Chinese Medicine, who delivered a keynote presentation titled "Global Progress on Holistic Cancer Care." Following his address, Oncology Frontier interviewed Prof. Louati to discuss his experience at the conference, his insights into the role of Traditional Chinese Medicine (TCM) in cancer treatment, and the promising prospects for China-Morocco collaboration in cancer research and prevention.

Dear colleagues in the medical field, the 14th Shanghai Genitourinary Oncology Academic Conference & Annual Meeting of Chinese Anti-Cancer Association-Genital Oncology Committee (CACA-GO) will be held grandly from December 6th to 8th ! This is a "highlight moment" in the field of urology. It focuses on the cutting-edge progress and innovative achievements. Many top-notch experts and scholars from both home and abroad will gather together to conduct in-depth discussions, covering multiple aspects such as surgical innovation, basic research, and translational medicine, presenting a veritable "feast" of academic knowledge.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, attracting leading experts, scholars, and industry leaders in cellular and immune therapies. This international platform not only fosters academic exchange but also showcases the latest research breakthroughs and drives progress in the field. During the conference, Dr. Yishan Ye from The First Affiliated Hospital of Zhejiang University School of Medicine shared his insights in an interview with Hematology Frontier. He discussed the principles of donor selection in allogeneic hematopoietic stem cell transplantation (allo-HCT) and the findings from the EBMT-China collaboration. Here is the interview in full.

The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier interviewed several prominent members of the advisory board who participated in the voting, including Prof. Yiding Chen, Prof. Hengyu Li, Prof. Man Li, Prof. Shu Liu, Prof. Yongsheng Wang, and Prof. Jian Zhang, to provide insights into the potential updates in the 2025 edition.

Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital to launch the Zhōng & Huì Insights clinical progress series. Through in-depth analyses of high-quality clinical research in lung cancer, the series aims to elevate clinical practice standards. In this 24th installment, the professors discuss the results of the study titled "Efficacy and Safety of Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients," published in The Lancet Respiratory Medicine by Dr. Baohui Han as the first author.